Using ultrasound to control drug delivery for bone healing
Ultrasound responsive hydrogels for stimulated combinatorial drug delivery
['FUNDING_R21'] · PENNSYLVANIA STATE UNIVERSITY, THE · NIH-10742110
This study is exploring a new way to help bones heal better by using special gels that release helpful proteins when treated with ultrasound, which could lead to faster and safer recovery for people with bone injuries.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PENNSYLVANIA STATE UNIVERSITY, THE (nih funded) |
| Locations | 1 site (UNIVERSITY PARK, UNITED STATES) |
| Trial ID | NIH-10742110 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to enhance bone healing by using ultrasound-responsive hydrogels that can deliver important growth factors, specifically Vascular Endothelial Growth Factor (VEGF) and Bone Morphogenic Protein (BMP). These hydrogels are designed to release these factors in a controlled manner when stimulated by focused ultrasound, which helps to improve blood vessel formation and bone regeneration. By precisely controlling the release of these proteins, the research aims to minimize side effects associated with uncontrolled drug delivery, such as inflammation and improper bone growth. Patients may benefit from improved healing outcomes in bone defects through this innovative treatment method.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with segmental bone defects or those requiring bone regeneration therapies.
Not a fit: Patients with stable bone conditions or those not requiring bone healing interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with bone defects, resulting in faster and safer healing.
How similar studies have performed: Other research has shown promise in using controlled drug delivery systems for bone regeneration, indicating that this approach could be a significant advancement in the field.
Where this research is happening
UNIVERSITY PARK, UNITED STATES
- PENNSYLVANIA STATE UNIVERSITY, THE — UNIVERSITY PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAYES, DANIEL J. — PENNSYLVANIA STATE UNIVERSITY, THE
- Study coordinator: HAYES, DANIEL J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.